University Hospital, Essen
uk-essen.deTotal trials
111
Active
30
Phase 3
5
Total enrollment
112,964
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Additional vaccination against shingles | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 2 | ||
| Amivantamab Intravenous | — | — | — | — | — | 1 | |
| Carboplatin/Pemetrexed | — | — | — | — | — | 1 | |
| Nivolumab 10 MG/ML Intravenous Solution | — | — | — | — | — | 1 | |
| Relatlimab 10 MG/ML Intravenous Solution | — | — | — | — | — | 1 | |
| Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps | — | — | — | — | — | 1 |
Next readouts
- 2025-03
- 2025-12
- 2027-07-31
- 2027-09
- 2029-12-31
Top conditions
- Heart Failure9
- Peripheral Arterial Disease7
- Coronary Artery Disease4
- Myocardial Infarction4
- Hereditary Hemorrhagic Telangiectasia3
- Aging3
- Coronary Heart Disease3
- Lung Cancer3
Frequently asked questions about University Hospital, Essen
- How many clinical trials does University Hospital, Essen have on ClinicalTrials.gov?
- University Hospital, Essen is listed as the lead sponsor on 111 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Essen's trials are in Phase 3?
- 5 of University Hospital, Essen's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does University Hospital, Essen focus on?
- University Hospital, Essen's most-studied conditions on ClinicalTrials.gov are Heart Failure, Peripheral Arterial Disease, Coronary Artery Disease, Myocardial Infarction, Hereditary Hemorrhagic Telangiectasia.
- When are University Hospital, Essen's next clinical trial readouts?
- University Hospital, Essen has 5 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients”, expected around 2025-03.